Predictive graphical model, network-based medical tool for the prognosis of chronic hepatitis C patients treated with peg-interferon plus ribavirin

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 4, 2008, Pages 468-474

  Trapero Marugan, M ^a   Marin, M ^b   Pivel, J P ^b   Del Rio, J M ^b   Nunez, O ^c   Clemente, G ^c   Gisbert, J P ^a   Moreno Otero, R ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ARTICLE; BAYES THEOREM; BIOINFORMATICS; CHRONIC HEPATITIS; COMPUTER GRAPHICS; DIAGNOSTIC ACCURACY; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; ROC CURVE; TREATMENT RESPONSE; VALIDATION PROCESS;

ALGORITHMS; ANTIVIRAL AGENTS; COMPUTATIONAL BIOLOGY; DECISION SUPPORT TECHNIQUES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RIBAVIRIN; ROC CURVE; TREATMENT OUTCOME;

EID: 47749099314     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03767.x     Document Type: Article

References (17)

1. Berry DA. Statistics: A Bayesian Perspective. Belmont, CA : Duxbury Press, 1996.
2. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP. Causal protein-signaling networks derived from multiparameter single-cell data. Science 2005 308 : 523 9.
3. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. West Sussex, UK : John Wiley & Sons, 2004.
4. Berry DA. Bayesian statistics. Med Decis Making 2006 26 : 429 30.
5. Millili JJ, Philiponis VS, Nusbaum M. Predicting surgical outcome using Bayesian analysis. J Surg Res 1998 77 : 45 9.
6. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989 244 : 359 62.
7. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000 20 : 1 16.
8. NIH Consensus Statement on Management of Hepatitis C. Management of Hepatitis C : 2002. NIH Consens State Sci Statements 2002 19 : 1 46.
9. Moreno-Otero R. Therapeutic modalities in hepatitis C: challenges and development. J Viral Hepat 2005 12 : 10 9.
10. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005 436 : 967 72.
11. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
12. Young H, Romero-Weaver AL, Savan R, Maher SG, Weiss J. Interferon-gamma. In : Zdanov A, ed. Class II Cytokines. Kerala, India : Transworld Research Network, Research Signpost, 2008.
13. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 55.
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 65.
15. Schurink CA, Visscher S, Lucas PJ, et al. A Bayesian decision-support system for diagnosing ventilator-associated pneumonia. Intensive Care Med 2007 33 : 1379 86.
16. Lucas PJ, van der Gaag LC, Abu-Hanna A. Bayesian networks in biomedicine and health-care. Artif Intell Med 2004 30 : 201 14.
17. van Gerven MA, Jurgelenaite R, Taal BG, Heskes T, Lucas PJ. Predicting carcinoid heart disease with the noisy-threshold classifier. Artif Intell Med 2007 40 : 45 55.